Drawing for NORDIC NANOVECTOR

USPTO serial 79230605

NORDIC NANOVECTOR

Reviewed by CopyMark Law Group

Reg. 5592658Status 709
Filing date
Status date
Registration date
Oct 30, 2018
Examiner
LAVACHE, LINDA M
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NORDIC NANOVECTOR?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Terrence J. McAllister

Terrence J. McAllister Ruggiero McAllister & McMahon LLCOne Landmark SquareStamford, CT 06901-2682UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances, namely, pharmaceutical preparations and substances for use in hematology, oncology and for the treatment of cancer; reagents for medical use; medical diagnostic chemicals and medical diagnostic reagents for medical use; antibody-based chemicals and reagents for medical use, namely, monoclonal antibodies, immuno-radiotherapies, antibody-radionuclide-conjugates; radiotherapies in the nature of chemotherapeutics that have a similar mechanism of action; diagnostic assay test kits for medical use consisting of medical diagnostic chemicals and reagents; biochemical preparations, namely, antibodies for medical diagnostic and therapeutic useSECTION 71 - CANCELLED—
042Medical and pharmaceutical research and development, namely, medical and pharmaceutical research and development in the field of hematology, oncology and the treatment of cancer; conducting clinical trials for others, namely, conducting clinical trials in the field of hematology, oncology and the treatment of cancer; providing medical research and scientific research information, namely, in the field of hematology, oncology and the treatment of cancerSECTION 71 - CANCELLED—
044Medical services; medical services in the field of healing, in particular diagnostic services in the field of hematology, oncology and the treatment of cancer; medical services, namely, immuno-radiotherapies and radiotherapies in the field of hematology, oncology and the treatment of cancerSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 3, 2026INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Aug 20, 2026INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 20, 2026INPCINVALIDATION PROCESSED—
Jan 16, 2026INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 16, 2025C71TCANCELLED SECTION 71—
Oct 30, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 18, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 18, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 18, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 18, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 16, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 15, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Feb 13, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 13, 2019FIMPFINAL DISPOSITION PROCESSED—
Jan 30, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 24, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 30, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 17, 2018GPNXNOTIFICATION PROCESSED BY IB—
Aug 14, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 14, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 1, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Aug 1, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jul 25, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 3, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 2, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 2, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 2, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 25, 2018RFNTREFUSAL PROCESSED BY IB—
May 7, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
May 7, 2018RFRRREFUSAL PROCESSED BY MPU—
May 3, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
May 2, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 1, 2018MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 27, 2018DOCKASSIGNED TO EXAMINER—
Apr 27, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 26, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance